Analysis of 1 Case of Drug Interaction of Paroxetine and Brain Protein Hydrolyzate

OBJECTIVE:To clarify the effective breakthrough point of roles which clinical pharmacists play in the clinical treatment. METHODS: Through clinical rounds, clinical pharmacists found that the combination between paroxetine and brain protein hydrolyzate may cause disruption. By searching a large number of documents, clinical pharmacists were informed that paroxetine was the P450 liver enzyme(CYP)2D6 inhibitors, which affected the brain protein hydrolyzate metabolism in vivo, causing adverse interaction. RESULTS: Clinical pharmacists proposed reasonable treatment options. After the physician adopted and implemented the program, the patient was discharged from hospital. CONCLUSION: In the clinical treatment, clinical pharmacists’ entry point can be adverse reactions in the treatment, and also can be medication compliance in patients and so on.